Amyris, Inc. (AMRS)
| Previous close | 0.0500 |
| Open | 0.0640 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0500 - 0.0643 |
| 52-week range | 0.0500 - 0.0643 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ReutersRetail investors flock to penny stocks WeWork, Amyris, Proterra
WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the financially struggling firms rising in strong trading volume after hitting record lows this week. The three penny stocks, up in the range of 40% to 120%, were the most actively traded U.S. shares at 10:45 a.m. ET on Friday. Amyris and WeWork were the second and third most traded stocks by retail investors, respectively, while Proterra was twelfth on the list at 10 a.m. ET, according to J.P.Morgan data.
- Reuters
Biotech firm Amyris files for bankruptcy in US
Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings. In a filing with the Delaware bankruptcy court, the company listed estimated assets in the range of $500 million to $1 billion and liabilities in the range of $1 billon to $10 billion. "Restructuring is intended to improve the Company's cost structure, capital structure, and liquidity position while streamlining Amyris' business portfolio to focus on its core competencies in R&D...," the company said.
Motley FoolIs It Time to Buy This Year's Worst-Performing Growth Stocks?
Ready to make sense of the market's laggards? The share prices of these high-octane growth stocks are falling in 2023, so it might be time to bet on rebounds -- but only some of them.
